Automatic differentiation of melanoma from melanocytic nevi with multispectral digital dermoscopy: A feasibility study - 09/05/12
Abstract |
Background: Differentiation of melanoma from melanocytic nevi is difficult even for skin cancer specialists. This motivates interest in computer-assisted analysis of lesion images. Objective: Our purpose was to offer fully automatic differentiation of melanoma from dysplastic and other melanocytic nevi through multispectral digital dermoscopy. Method: At 4 clinical centers, images were taken of pigmented lesions suspected of being melanoma before biopsy. Ten gray-level (MelaFind) images of each lesion were acquired, each in a different portion of the visible and near-infrared spectrum. The images of 63 melanomas (33 invasive, 30 in situ) and 183 melanocytic nevi (of which 111 were dysplastic) were processed automatically through a computer expert system to separate melanomas from nevi. The expert system used either a linear or a nonlinear classifier. The “gold standard” for training and testing these classifiers was concordant diagnosis by two dermatopathologists. Results: On resubstitution, 100% sensitivity was achieved at 85% specificity with a 13-parameter linear classifier and 100%/73% with a 12-parameter nonlinear classifier. Under leave-one-out cross-validation, the linear classifier gave 100%/84% (sensitivity/specificity), whereas the nonlinear classifier gave 95%/68%. Infrared image features were significant, as were features based on wavelet analysis. Conclusion: Automatic differentiation of invasive and in situ melanomas from melanocytic nevi is feasible, through multispectral digital dermoscopy. (J Am Acad Dermatol 2001;44:207-18.)
Le texte complet de cet article est disponible en PDF.Plan
Supported in part by grant numbers 2R44 CA/AR60229-02, 1R43 CA74628-01 and 2R44 CA74628-02 from the National Cancer Institute to Electro-Optical Sciences, Inc, and by the Christopher Columbus Fellowship Foundation Award for 1998 (to M. E.). |
|
The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. |
|
Reprint requests: Marek Elbaum, PhD, EOS, 1 Bridge St, Suite 15, Irvington, NY 10533. E-mail: elbaum@eo-sciences.com. |
|
J Am Acad Dermatol 2001;44:207-18 |
Vol 44 - N° 2P1
P. 207-218 - février 2001 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?